Drug Trial Radar · NCT06386744
Dusquetide for the Treatment of Behcet's Disease
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Nov 18, 2024
Primary completion
May 23, 2025
Study completion Jun 17, 2025
Sponsor
- Lead sponsor
- SoligenixIndustry
- Sponsor type
- Industry
- First posted
- Apr 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks.
Conditions
- Behçet Disease
Interventions
DusquetideDrug
1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Oral UlcersTime frame: 4 weeks
- Number of Genital UlcersTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.